Moderna Collaborated with Carisma to Develop CAR-M Therapies for the Treatment of Cancer
Shots:
- Carisma to receive a $45M up front along with research funding & is eligible to receive development, regulatory, and commercial milestone along with royalties on net sales of the products
- The collaboration combines Moderna’s expertise in mRNA and LNP technologies with Carisma's expertise in engineered macrophage biology to develop in vivo CAR-M therapeutics for the treatment of cancer
- Carisma will lead the discovery and optimization of development products while Moderna gets an option to nominate ~12 targets & will be responsible for clinical development and commercialization of therapeutics that emerges from the collaboration
Ref: PR Newswire | Image: Moderna
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com